Quick Answer
Contineum Therapeutics, Inc. reported R&D Expense of $51.52 million for fiscal year 2025.
Contineum Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $51.52M | +34.1% |
| 2024 | $38.42M | +39.2% |
| 2023 | $27.60M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $10.99M | +13.0% | -21.8% |
| June 30, 2025 | $14.06M | +78.0% | +2.6% |
| March 31, 2025 | $13.71M | +76.3% | +41.0% |
| September 30, 2024 | $9.73M | +49.7% | +23.1% |
| June 30, 2024 | $7.90M | -16.5% | +1.6% |
| March 31, 2024 | $7.78M | +114.2% | +19.7% |
| September 30, 2023 | $6.50M | — | -31.3% |
| June 30, 2023 | $9.46M | — | +160.5% |
- Contineum Therapeutics, Inc. showed an increase of +34.1% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, Contineum Therapeutics, Inc.’s r&d expense has grown by 86.7% (from $27.60 million to $51.52 million).
- The most recent figure is from Contineum Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: